Valeant to buy Obagi Medical for about $344 mln
March 20 (Reuters) - Canadian drugmaker Valeant Pharmaceuticals International Inc said it would buy Obagi Medical Products Inc for about $344 million to boost its dermatology and aesthetics portfolio.
The deal, at $19.75 per share in cash, is at a 28 percent premium to Obagi's Tuesday closing price.
Obagi's board has unanimously approved the deal, Valeant said in a statement.
© Thomson Reuters 2017 All rights reserved.